HitGen and SPARC Enter DNA-Encoded Library Based Innovative Drug Discovery Research Collaboration Release Time：2019-03-13

CHENGDU and MUMBAI –March 13, 2019,HitGenLtd. and Sun Pharma Advanced Research Company Ltd. (SPARC)(Reuters: SPRC.BO, Bloomberg: SPADV IN, NSE: SPARC, BSE: 532872) todayannounced a research collaboration toidentifynovel small molecule leads for targets of interest.Under this collaboration,HitGen will apply its advanced technology platform, based on DNA-encoded library design, synthesis and screening, to discover novel leads forSPARC. Under the terms of the agreement,HitGenwill receive upfrontpaymentand will be eligible for certainmilestone payments.

“We are delighted to enter into collaboration with SPARC,a global pharmaceutical company headquartered in Mumbai.This collaboration further emphasizes the role of HitGen in the rapidly developing field of DNA-encoded chemistry. We will work closely with SPARC scientists to generate novel leads for their innovative research programs to address unmet medical needs.” said Dr.Jin Li, Chairman of the Board and Chief Executive Officer ofHitGen.

“We believe HitGen’s unique DNA-encoded library based screening platform combined with SPARC’s in-house research expertise, shall accelerate our drug discovery efforts. We look forward to collaborating with HitGen to bring innovative medicines for patients with serious medical conditions.”said Anil Raghavan, CEO of SPARC.“

About HitGen Ltd

HitGen isa rapidly growing biotechcompanywith headquarters and main research facilitiesbased in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecule drug discoverycentred onthe design, assembly and interrogation of DNA encodedchemicallibraries(DELs). HitGen’sDELscontain nearly 400billion novel, diverse, drug-likesmall molecule and macrocycliccompounds. These compounds are members of DELssynthesised frommany hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads againstprecedented and unprecedented classes ofbiological targets.HitGen is collaborating with pharmaceutical, biotech, and chemical companies, foundations and research institutes in North America, Europe, Asia andAfrica to discover and develop approaches for novel medicines and agrochemical solutions. For more information, please visitwww.hitgen.com

About SPARC (CIN: L73100GJ2006PLC047837):

Sun Pharma Advanced Research Company Ltd. (SPARC) is a global pharmaceutical company focused on continuously improving standards of care for patients globally through innovation in therapeutics and delivery. SPARC aims to consistently lower costs and improve operational efficiencies to advance availability and affordability of cures for patients across the world. More information about the company can be found at www.sparc.life

Disclaimer:

Statements in this document describing the Company’s objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be “forward looking statements” within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied.

Media Contacts:

HitGen

Dr. Jin Li

Chairman & CEO,HitGen Ltd.

Tel: +86 28 85197385 (8001)

Email: jin.li@hitgen.com

SPARC

Jaydeep Issrani

Tel +91 22 66455645, Extn: 5787

Tel Direct +91 22 6645 5787

Mobile +91-9820216916

Email: jaydeep.issrani@sparcmail.com